|
Time
|
Program/Title
|
Speaker
|
|
Opening
|
|
9:00 - 9:30
|
Opening
remark by IPK CEO Dr. Youngmee Jee, PDI Director Prof. Sharon Lewin
|
|
Congratulatory remark by Ministry of Science
and ICT, Australian Embassy and French Embassy
|
|
Session I: Antimicrobial Resistance and
Genomics
Chair: Spencer Shorte(IPK) & Peter Revill(PDI)
|
|
9:30 - 9:45
|
Staphylococcus
aureus antibiotic resistance
|
Tim Stinear (PDI)
|
|
9:45 - 10:00
|
A
battle against antibiotic resistance: from basic science to applications
|
Soojin Jang (IPK)
|
|
10:00 - 10:15
|
Genomics for AMR
Surveillance
|
Norelle Sherry (PDI)
|
|
10:15 -
10:35
|
Coffee break
|
|
Session II: Everlasting
Battle with Viruses
Chair: Youngmee Jee (IPK) & Sharon
Lewin (PDI)
|
|
10:40
- 10:55
|
Surveillance and Research activities at
the Melbourne WHO Collaborating Center for
Reference & Research on Influenza
|
Ian Barr (PDI)
|
|
10:55
- 11:10
|
Immune evasion of human cytomegalovirus by
lymphoid cell death
|
Eungsoo Hwang (IPK)
|
|
11:10 - 11:25
|
The road towards
hepatitis B cure
|
Peter Revill (PDI)
|
|
11:25 - 11:40
|
Characterization of a cellular model of HBV
infection
|
Kyuho Paul Park (IPK)
|
|
11:35 -
1:00
|
Lunch
|
|
Session III: COVID-19 Response
Chair: Eungsoo Hwang(IPK) & Norelle Sherry (PDI)
|
|
1:05 - 1:20
|
Collaborative
Efforts for COVID-19 Drug Development
|
Seungtaek Kim (IPK)
|
|
1:20 - 1:35
|
The role of animals
in COVID-19 research and response
|
Danielle Anderson (PDI)
|
|
1:35 - 1:50
|
Analysis
of the immune response to COVID-19 vaccination
|
Euiho Kim (IPK)
|
|
1:50 - 2:05
|
CRISPR Cas13 as an
antiviral for SARS CoV2 and other pathogens
|
Sharon Lewin (PDI)
|
|
Session IV: Technologies for Infectious Diseases
Chair:
Regis Grailhe(IPK) & Tim Stinear(PDI)
|
|
2:05 -
2:20
|
Technology & Innovation for Pandemic Response
|
David Shum (IPK)
|
|
2:25 -
2:40
|
HIV-1 RNA-biology and evolution reveal
strategies for antiviral therapies and vaccines.
|
Damian Purcell (PDI)
|
|
2:40 -
2:55
|
What’s in an image?: Rethinking our
approach to high-content screening for bioactivities and drug discovery
|
Spencer Shorte (IPK)
|
|
Closing
Closing remarks by IPK CEO Dr. Youngmee
Jee, PDI Director Prof. Sharon Lewin
|
